Dr. Robert J. Pignolo, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Perelman School of Med at the University of Pennsylvania (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 16
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: Perelman School of Med at the University of Pennsylvania
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
MN license 61175 -
Geriatric Medicine (Internal Medicine) Physician
MN license 61175
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Hospital Rochester Rochester, MN
Medical groups
- Mayo Clinic (4,956 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 16
- Services billed
- 34
- Patients’ average age
- 82
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 28 | 13 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 25 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 2 companies reported 6 payments worth $14,244 in total to this clinician.
| Ipsen Biopharmaceuticals, Inc | $13,358 |
|---|---|
| Regeneron Pharmaceuticals, Inc. | $886 |
| Compensation for services other than consulting (speaking, faculty) | $9,900 |
|---|---|
| Travel and Lodging | $4,096 |
| Food and Beverage | $248 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc Jan 1, 2025 | Compensation for services other than consulting (speaking, faculty) Sohonos · Rare Disease | $9,900 |
| Ipsen Biopharmaceuticals, Inc Jan 1, 2025 | Travel and Lodging Sohonos · Rare Disease · travel to Denver, CO · in-kind | $2,472 |
| Regeneron Pharmaceuticals, Inc. Dec 30, 2025 | Travel and Lodging travel to ATLANTA, GA · in-kind | $851 |
| Ipsen Biopharmaceuticals, Inc Jan 1, 2025 | Travel and Lodging Sohonos · Rare Disease · travel to Denver, CO · in-kind | $738 |
| Regeneron Pharmaceuticals, Inc. Dec 30, 2025 | Travel and Lodging travel to ATLANTA, GA · in-kind | $35.25 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $578,415 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
Ipsen Innovation · Terminated · NCT05039515 - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
Incyte Corporation - Study name not reported
GlaxoSmithKline, LLC. - FOPal -An International Observational Registry Study
Ipsen Biopharmaceuticals, Inc - A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.
Ipsen Pharma Sas · Completed · NCT05027802
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.